@FierceBiotech: Stallergenes beats Merck to market as the FDA OKs its allergy pill. More | Follow @FierceBiotech
@JohnCFierce: Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696. News | Follow @JohnCFierce
@DamianFierce: MannKind jumps ~125% after positive panel vote, reaching a four-year high. Story | Follow @DamianFierce
@EmilyMFierce: Most popular at FierceBiotechResearch.com: Committee finds 'scientific misconduct' in blockbuster stem cell papers. Article | Follow @EmilyMFierce
> Johnson & Johnson ($JNJ) is seeking FDA approval for a fixed-dose combination of its HIV treatment darunavir and Gilead Sciences' ($GILD) investigational cobicistat. News
> Tetraphase Pharmaceuticals ($TTPH) secured the FDA's fast-track designation for both oral and intravenous formulations of its antibiotic eravacycline, designed to treat complicated urinary tract and intra-abdominal infections. More
> Alzheimer's drug developer EnVivo Pharmaceuticals has changed its name to Forum Pharmaceuticals. Item
@FierceMedDev: Four months later 23andMe's clash with the FDA over regulation of OTC genetic tests remains unresolved. Story | Follow @FierceMedDev
@MarkHFierce: Check out the latest FierceDiagnostics, with news involving Pfizer, colon cancer tests and HIV Dx funding. Report | Follow @MarkHFierce
@MichaelGFierce: In drug delivery, it's the little things that count. Looking back on the year in nanotech drug delivery. Special report | Follow @MichaelGFierce
@EmilyWFierce: Researchers at Cornell delve into "cereal box psychology" with new study on supermarkets and spokes-characters. Article | Follow @EmilyWFierce
> Thoratec smacked with FDA Class I recall concerning heart pump backup controllers. More
> Boston Scientific touts promising trial data for its transcatheter valve. Story
> Cepheid's 60-minute HPV test is now available in Europe. Item
Pharma News
@FiercePharma: Industry predicts dire consequences from FDA's generic labeling proposal. News | Follow @FiercePharma
@TracyStaton: GSK ditches ovarian cancer plans for Votrient after failed study. More | Follow @TracyStaton
@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. Article | Follow @EricPFierce
@CarlyHFierce: Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up- FiercePharmaMarketing. Story | Follow @CarlyHFierce
> Amarin triples size of Vascepa sales force with Kowa promo deal. More
> ViiV adds pricey new HIV drug Tivicay to patent pool. News
> Can Auxilium's ED hopeful Stendra score with provocative March Madness ads? Item
Drug Delivery News
> Enzyme micropumps deliver insulin in response to glucose levels. Story
> Hydrogel delivers inhibitors directly to reduce damage after a heart attack. Article
> Harvard researchers create method to measure nano exposure for safety, delivery. News
> Water excited by infrared light melts nanoparticles to release drugs. Article
> DNA nanorobot delivers drugs through flap that opens and closes. Story
> Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Brief
Diagnostics News
> Pfizer leads $21M Series B for a Michigan molecular Dx startup. News
> Exact Sciences' and Epigenomics' colon cancer tests clear FDA panel with mixed results. News
> New septic shock biomarker Dx could produce better care and smoother drug trials. Article
> U.K. team scores with blood test that might spot children likely to become obese. Story
> Zyomyx snags $7.5M from WHO's UNITAID to fund HIV/AIDS test in emerging markets. News
> Finding: 2 biomarkers for head and neck cancer can help predict radiation therapy resistance. Brief
Pharma Marketing News
> Sanofi aims for outcomes with brand-new Chief Patient Officer. Story
> Eli Lilly's sales force finds CRM harmony in the cloud. Article
> Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up. Story
> Can statin-maker Kowa help Amarin jump-start Vascepa sales? Article
> Auxilium aims Stendra's sexy March Madness ads at stiff ED competition. Story
> ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries. Brief